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Abstract
Background: Previous studies have proposed a simple product-based estimator for calculating exposure-specific
risks (ESR), but the methodology has not been rigorously evaluated. The goal of our study was to evaluate the
existing methodology for calculating the ESR, propose an improved point estimator, and propose variance
estimates that will allow the calculation of confidence intervals (CIs).
Methods: We conducted a simulation study to test the performance of two estimators and their associated
confidence intervals: 1) current (simple product-based estimator) and 2) proposed revision (revised product-based
estimator). The first method for ESR estimation was based on multiplying a relative risk (RR) of disease given a
certain exposure by an overall risk of disease. The second method, which is proposed in this paper, was based on
estimates of the risk of disease in the unexposed. We then multiply the updated risk by the RR to get the revised
product-based estimator. A log-based variance was calculated for both estimators. Also, a binomial-based variance
was calculated for the revised product-based estimator. 95% CIs were calculated based on these variance
estimates. Accuracy of point estimators was evaluated by comparing observed relative bias (percent deviation from
the true estimate). Interval estimators were evaluated by coverage probabilities and expected length of the 95% CI,
given coverage. We evaluated these estimators across a wide range of exposure probabilities, disease probabilities,
relative risks, and sample sizes.
Results: We observed more bias and lower coverage probability when using the existing methodology. The
revised product-based point estimator exhibited little observed relative bias (max: 4.0%) compared to the simple
product-based estimator (max: 93.9%). Because the simple product-based estimator was biased, 95% CIs around
this estimate exhibited small coverage probabilities. The 95% CI around the revised product-based estimator from
the log-based variance provided better coverage in most situations.
Conclusion: The currently accepted simple product-based method was only a reasonable approach when the
exposure probability is small (< 0.05) and the RR is ≤ 3.0. The revised product-based estimator provides much
improved accuracy.
Background
Exposure-specific risk (ESR) is defined as the risk of dis-
ease (or any outcome) given a specific exposure (or sub-
group). ESRs are useful to clinicians because it allows a
much more meaningful way of explaining risk to
patients. They are also useful to investigators who are
looking to use ESRs for their own work, which may
include publishing their own work or planning studies.
In the absence of having access to the primary data or a
reported estimate of the ESR in the literature, the ESR
can be estimated from two independent samples if the
investigator knows the overall risk of disease and the
relative risk (RR) of disease given the exposure of inter-
est. There have been a number of published studies
where ESRs have been calculated from two independent
samples by multiplying the overall risk of disease from
one sample by the RR from a second independent sam-
ple [1,2]. Stewart et al. computed the ESR of hip fracture
given certain exposures (prior fracture, family history of
fracture, low body weight, and smoking) in persons over
the age of 70 in the United Kingdom [2]. This study
found that the ESR of hip fracture among those with all
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4 exposures was 8.9%. This was done by multiplying an
overall risk of hip fracture of 1.91% by a RR of 4.66 [2].
Horsburgh computed the ESR of tuberculosis for mul-
tiple risk factors, along with 95% confidence intervals
(CIs). The upper (lower) bound of the 95% CI for the
ESR was calculated by multiplying the upper (lower)
bound of the 95% CI for the overall risk by the upper
(lower) bound of the 95% CI for the RR [1]. While there
has been some work addressing the multiplication of
two binomial parameters [3], to the best of our knowl-
edge, there are no methodological articles evaluating the
properties of the simple product-based estimator that
was used in the articles by Stewart et al and Horsburgh.
In this article we set to address three objectives. The
first is to evaluate the properties of the simple product-
based estimator of the ESR used by Stewart et al and
Horsburgh. The second objective is to propose an esti-
mate of the variance of the ESR, which can subsequently
be used for calculating 95% CIs. Lastly, we propose a
revised product-based estimator and two variances esti-
mates for the revised point estimator which are used to
calculate 95% CIs.
Methods
Overview
We designed and implemented a simulation study to
examine the properties of two different estimators of
the ESR and their 95% CIs. The two estimators we
sought to evaluate (and their associated CIs) were a sim-
ple product-based estimator and revised product-based
estimator. Point estimators were evaluated by calculating
the observed relative bias. Their 95% CIs were evaluated
using coverage probabilities and expected length given
coverage for a wide range of parameters, including
exposure probability, probability of disease among the
unexposed, the RR of disease given exposure, and the
sample size.
For the purposes of this paper, D represents having
disease, E represents having exposure, subscript one
denotes that the quantity comes from sample one, and
subscript two denotes that the quantity comes from
sample two. More careful examination of the mathe-
matics behind this simple product-based estimator
clearly shows that the estimator is at best a crude
approximation of the ESR.
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To estimate the ESR, this formula needs an estimate
of the risk of disease in the unexposed (P (D|E1 ) ) rather
than the estimate of the overall risk of disease (P1(D)).
Simple Product-Based ESR
The simple product-based ESR (denoted ESRS) is com-
puted by simply multiplying the overall probability of
disease from sample one by the RR from sample two.
The formula is given below.
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Variance and Confidence Interval for the Simple Product-
Based ESR
We first propose a formula for the variance of the sim-
ple product-based estimator using a natural log transfor-
mation. We assumed that the covariance between ln(P1
(D)) and ln(RR2) was zero because they are estimated
from independent data sets.
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To complete the formula for the variance of the nat-
ural log ESR we need the variance of the natural log of
the overall risk (Var(In(P1(D)))). This is derived below
using the delta method.
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Substituting the result of equation 4 into equation 3
and we have the final variance for the natural log of the
ESR:
Var(ln(ESR ))
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Because we tested our confidence intervals for sample
sizes that were 250 or larger, the central limit theorem
applies and we can use a normal approximation for
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estimating the 95% confidence interval.
95% CI exp ln(ESR ) 1.96* Var(ln(ESR ))S S= ±( ) (6)
Revised Product-Based ESR
Note, from formula 1, we need an estimate of the risk of
disease in the unexposed from sample 1 ( P (D|E1 ) ),
rather than the estimate of the overall risk of disease (P1
(D)). Assuming that the risk of disease in the unexposed
is not reported from sample 1 or sample 2, we can use
the law of total probability to derive P (D|E1 ) . By the
law of total probability the following formula holds.
P(D) P(D|E)*P(E) P(D|E)*P(E)
RR*P(D|E)*P(E) P(D|E)*(1-P(E)
= +
= + )  
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Next, solving for P(D|E) gives us:
P(D|E)
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=
+
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Here, estimates of P1(D)), P2(E), and RR2 are available in
samples one and two as denoted by the subscripts. Then
the final estimate for the revised product-based ESR is
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P (D)
[((RR -1)*P (E)) 1]
RRR
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+
* .2 (9)
Variance and Confidence Interval for the Revised Product-
Based ESR
The first estimate of variance derived for the revised
product-based is derived for the natural log of the esti-
mate. This is done similar to the derivation for the var-
iance of the natural log of ESRs shown in equation 5.
The exception is that now we need to find variance of
the natural log of the probability of disease among the
unexposed in sample 1.
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Thus a 95% CI for ESRR can be constructed using the
normal approximation shown in equation 6 by substitut-
ing ESRR for ESRS and Var(ln(ESRR)) for Var(ln(ESRS)).
Since the ESR is a probability, the second estimate of
the variance derived for ESRR is based on the binomial
distribution. The variance for a binomial parameter p is
p*(1 p)
n
− . We chose to estimate the denominator of
this formula by multiplying the sample size from sample
1 by the exposure probability from sample 2. This pro-
vides a more conservative estimate of the variance
because the denominator will be smaller. The final forms
of this variance and the 95% CI using a normal approxi-
mation to the binomial distribution are shown below.
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Simulation study details
All simulations and subsequent evaluations were per-
formed using SAS statistical software, version 9.2 (SAS,
Cary, NC). Populations of size 10 million were generated
based on different exposure probabilities, probabilities of
disease among the unexposed, and RRs of disease given
the exposure. One thousand pairs of samples were drawn
from the population to determine the sampling distribu-
tion of the overall probability of disease and the RR of dis-
ease given exposure. After the samples were generated,
estimates of the RR and overall probability of disease
(along with their 95% CIs) were calculated for each sample.
For the purposes for this report we organize the
results into four scenarios. Scenario 1 considers the
situation where the exposure probability was low (.05)
and the probability of disease among the unexposed was
low (.02). Scenario 2 considers the situation where the
exposure probability was low (.05) and the probability of
disease among the unexposed was moderate (.09). Sce-
nario 3 considers the situation where the exposure prob-
ability was high (.20) and the probability of disease
among the unexposed was low (.02). Scenario 4 consid-
ers the situation where the exposure probability was
high (.20) and the probability of disease among the
unexposed was moderate (.09). For all four scenarios we
evaluated the properties of the two point estimators and
three interval estimators across seven different RRs and
four different sample size combinations (Table 1). We
chose larger sample sizes because the probability of dis-
ease in the unexposed was low (.02) or moderate (.09)
and investigators who perform this calculation would
want to use the highest quality estimate available. Lastly,
in order to evaluate properties of our estimates when
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the sample size was small, we ran our simulations with a
sample size of 250 for both sample 1 and sample 2
under the conditions of Scenario 4 only. We did not
perform this analysis in the other three scenarios
because the prevalence of exposure and disease among
the unexposed was too small to provide a reliable esti-
mate of the RR.
Evaluation of ESR Estimators
We calculated the estimated ESR using the simple pro-
duct-based method and revised product-based method
for each of the 1,000 pairs of samples. We evaluated the
estimators using observed relative bias. Observed rela-
tive bias was defined as the difference between the aver-
age of the 1,000 estimates from the 1,000 pairs of
samples and the assumed population ESR divided by the
assumed population ESR. Observed relative bias can be
described as the percent change from the true estimate.
Evaluation of Confidence Intervals
All 95% CIs were evaluated using coverage probabilities.
The coverage probability is defined as the probability
that the interval covers the assumed population ESR.
For each of the 1,000 pairs of samples we determine
whether the assumed population ESR falls between the
lower and upper bounds of the CI. The coverage prob-
ability is then determined by the number of times the
interval covered divided by 1,000. Since we calculated
95% CIs, we expect that our intervals would cover 950
times out of 1,000 (95%).
Expected length given coverage was also evaluated for
all of our 95% CIs. For every 95% CI that covered the
true value of the ESR for a given pair of 1,000 samples,
the length was calculated by subtracting the lower
bound from the upper bound. We then calculated the
average of these lengths to get the expected length given
coverage. For example, if the coverage probability was
95.1% then 951 out of 1,000 intervals covered the true
value of the ESR. Therefore the expected length given
coverage is based on an N of 951. For the purpose of
comparison, we also calculated the empirical 95% CI
and its length. This was done by examining the distribu-
tion of the direct estimator and taking the 2.5th percen-
tile to be the lower bound of the 95% CI and the 97.5th
percentile to be the upper bound of the 95% CI. The
length of the empirical 95% CI was calculated by sub-
tracting the 2.5th percentile from the 97.5th percentile.
Case Study
We tested our methodology using a case study in which
we calculated the risk of symptomatic knee osteoarthri-
tis (OA) in obese persons by age groups. The overall
risk of symptomatic knee OA by age group was derived
from Oliveria et al [4]. This article reports on one of the
largest population-based studies that estimates the risk
of symptomatic knee OA with a cohort of more than
130,000 members of a community health plan. The rela-
tive risk of symptomatic knee OA for obese persons
(1.91) and proportion obese (0.371) was derived from
Niu et al [5]. This study provides one of the most cur-
rent estimates of the relative risk of symptomatic knee
OA by obesity status and also had a substantial sample
size (N = 2,660). Since the study by Niu and colleagues
only studied those ages 50-79, we limited our analysis to
those ages 50-59, 60-69, and 70-79.
Results
Scenario 1: Low exposure probability (.05)/Low disease
probability among unexposed (.02)
In the case where the probability of exposure was low
(.05) and the probability of disease among the unex-
posed was low (.02), ESRR performed better than ESRS
with respect to observed relative bias. When the RR was
1.0, the observed relative bias was near 0 for both esti-
mators. However, as the RR increased the observed rela-
tive bias of ESRS increased. This increased to a high of
31.4% when the RR was 5.0 and both sample sizes were
1,000. In the same situation, ESRR exhibited an observed
relative bias of 3.4%. In general, as the RR increased in
magnitude so did the observed relative bias of ESRS,
while the observed relative bias of ESRR was not larger
than 4.0% (Table 2).
Coverage probabilities for the 95% CI of ESRS were at
least 95% when the RR was 2.0 or less, regardless of the
sample size combination. However, as the RR increased
(and subsequently the observed relative bias), the cover-
age probabilities began to fall below 95%. The coverage
probability fell to 87.1% when the RR was 5.0 and both
sample sizes were 5,000 (Table 3). Coverage probabilities
for the 95% CI for ESRR using a log-based variance were
Table 1 Parameters varied and all their possible values for the simulation study
Parameter Possible values
Exposure probability .05, .20
Probability of disease among unexposed .02, .09
RR 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0
Sample size combinations for the overall risk and RR (N1/N2) 250/250*, 1,000/1,000, 1,000/5,000, 5,000/1,000, 5,000/5,000
*Note: The 250/250 sample size combination was only performed in Scenario 4 (probability of exposure = .20; probability of disease among unexposed = .09).
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above 95% across all RRs for three of the four sample
size combinations (N1 = 1,000, N2 = 1,000; N1 = 5,000,
N2 = 1,000; and N1 = 5,000, N2 = 5,000). When the
sample size combination was 1,000 for the overall risk
(sample 1) and 5,000 for the RR (sample 2) the 95% CI
for ESRR using a log-based variance failed to attain 95%
coverage for all RRs (see additional file 1). The exact
opposite relationship was observed for the 95% CI of
ESRR using a binomial variance. This interval only
attained 95% coverage when the sample size combina-
tion was 1,000/5,000. In fact, these coverage probabil-
ities well exceeded 95% with the smallest coverage
probability being 98.9% when the RR was 1.0 (Table 4).
Figure 1 shows the expected lengths given coverage of
all the 95% CIs constructed by different RRs (1.0, 2.0,
and 5.0 respectively) for the 5,000/5,000 (N1/N2) sample
size combination. The expected length of the empirical
95% CI is also shown. The expected length given cover-
age is largest for the 95% CI around ESRS, and the bino-
mial-based variance yielded 95% CIs around ESRR with
smaller lengths than the log-based variance 95% CIs in
this scenario.
Scenario 2: Low exposure probability (.05)/Moderate
disease probability among unexposed (.09)
Increasing the probability of disease among the unex-
posed from .02 to .09 while keeping the exposure prob-
ability set to .05 did not drastically change our results.
The observed relative bias of ESRS still increased as the
magnitude of the RR increased. When the RR was 5.0,
Table 2 Observed relative bias for the simple product-based estimator (ESRS) and the revised product-based
estimator (ESRR)
Low exposure probability (.05)/Low disease probability in unexposed (.02)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.02 9.5% 3.9% -1.4% -2.3%
2.0/.04 7.8% -2.6% 4.5% -1.4%
3.0/.06 18.0% 1.8% 12.2% 0.8%
4.0/.08 21.1% 0.0% 17.6% 1.1%
5.0/.10 31.4% 3.4% 22.6% 1.0%
Low exposure probability (.05)/Moderate disease probability in unexposed (.09)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.09 0.1% -0.9% 0.9% 0.6%
2.0/.18 6.1% 0.1% 5.5% 0.3%
3.0/.27 9.2% -1.4% 10.4% 0.2%
4.0/.36 16.6% 0.4% 15.9% 0.5%
5.0/.45 22.0% 0.7% 21.2% 0.8%
High exposure probability (.20)/Low disease probability in unexposed (.02)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.02 8.7% 1.1% -0.2% -1.3%
2.0/.04 26.3% -1.4% 21.4% -0.1%
3.0/.06 45.0% -1.8% 41.7% 0.1%
4.0/.08 73.3% 1.2% 61.6% 0.1%
5.0/.10 93.9% 0.3% 82.5% 0.0%
High exposure probability (.20)/Moderate disease probability in unexposed (.09)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.09 -0.8% -0.4% -1.1% -1.0%
2.0/.18 22.6% 0.7% 20.4% 0.2%
3.0/.27 40.9% -0.2% 40.3% 0.0%
4.0/.36 63.6% 0.7% 60.6% 0.1%
5.0/.45 82.6% 0.2% 81.0% 0.2%
N1 is the sample the overall risk is derived from.
N2 is the sample the relative risk is derived from.
Relative Risk/Exposure-Specific Risk (RR/ESR) values are the hypothesized values.
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the observed relative bias of ESRS was greater than 20%
for all sample size combinations. The observed relative
bias of ESRR was close to zero for all combinations of
RR and sample size (Table 2).
Coverage probabilities for the 95% CI of ESRS were
less than 95% in most cases. The coverage probabilities
were adversely affected by the increasing magnitude of
the RR with a minimum coverage probability of 45%
attained when the RR was 5.0 and the sample size was
5,000 for both samples (Table 3). Similar to Scenario 1,
coverage probabilities for the 95% CI of ESRR using a
log-based variance exhibited at least 95% coverage in all
cases except when the sample size the overall risk was
derived from was 1,000 and the sample size the RR was
derived from was 5,000 (see additional file 1). The 95%
CI for ESRR using a binomial variance showed the exact
opposite relationship. Regardless of the magnitude of
the RR, the coverage probability of the 95% CI for ESRR
using a binomial variance was greater than 99% when
the sample size the overall risk was derived from was
1,000 and the sample size the RR was derived from was
5,000 (Table 4).
Figure 2 shows the expected lengths given coverage of
the 95% CIs. The expected length given coverage
increases for all the intervals as the magnitude of the
RR increases. The expected lengths of the 95% CIs of
ESRS and ESRR using a log-based variance are similar
when the RR is small. However, as the RR increases in
Table 3 Coverage probability for the 95% confidence interval of the simple product-based estimator (ESRS) and
revised product-based estimator (ESRR) using a log-based variance
Low exposure probability (.05)/Low disease probability in unexposed (.02)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.02 96.8 97.3 97.5 97.5
2.0/.04 96.4 98.1 95.9 97.2
3.0/.06 95.7 98.3 92.7 96.6
4.0/.08 94.1 98.2 90.3 98.0
5.0/.10 93.9 98.4 87.1 97.7
Low exposure probability (.05)/Moderate disease probability in unexposed (.09)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.09 96.8 97.2 95.9 96.2
2.0/.18 95.8 96.8 93.4 96.3
3.0/.27 94.3 97.0 87.8 96.4
4.0/.36 89.3 96.1 70.8 97.0
5.0/.45 83.2 96.6 45.0 96.6
High exposure probability (.20)/Low disease probability in unexposed (.02)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.02 97.6 98.5 94.5 96.6
2.0/.04 94.2 98.9 85.6 98.0
3.0/.06 89.5 99.0 55.1 98.6
4.0/.08 76.8 99.2 22.3 99.4
5.0/.10 65.4 99.6 4.2 99.4
High exposure probability (.20)/Moderate disease probability in unexposed (.09)
N1 = 1,000, N2 = 1,000 N1 = 5,000, N2 = 5,000
RR/ESR ESRS ESRR ESRS ESRR
1.0/.09 94.7 96.8 94.7 96.5
2.0/.18 85.4 98.5 51.1 98.0
3.0/.27 55.9 98.5 1.8 98.6
4.0/.36 17.6 99.4 0 99.4
5.0/.45 2.9 99.5 0 99.4
N1 is the sample the overall risk is derived from.
N2 is the sample the relative risk is derived from.
Relative Risk/Exposure-Specific Risk (RR/ESR) values are the hypothesized values.
Italics denote coverage probabilities that did not attain 95%.
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magnitude, the length of the 95% CI for ESRS is greater
than the length of the 95% CI for ESRR using a log-
based variance.
Scenario 3: High exposure probability (.20)/Low disease
probability among unexposed (.02)
Increasing the exposure probability from .05 to .20 while
the probability of disease among the unexposed was .02
affected the results substantially for the existing metho-
dology. The observed relative bias of ESRS was over 10%
when the RR was 1.5, over 20% when the RR was 2.0,
and over 80% when the RR was 5.0. However, the
observed relative bias of ESRR was near 0% with the
greatest observed relative bias being -1.8% when the RR
was 3.0 and both sample sizes were 1,000 (Table 2).
In terms of coverage probability, the 95% CI for ESRS
attained 95% coverage only when the RR was small.
When the RR was 5.0, the 95% CI for ESRS had a cover-
age probability as low as 4.2% when the sample size was
5,000 for both samples. Similar to the previous two ana-
lyses, coverage probabilities for the 95% CI of ESRR
using a log-based variance exhibited at least 95% cover-
age in all cases except when the sample size the overall
risk was derived from was 1,000 and the sample size the
RR was derived from was 5,000 (see additional file 1).
The 95% CI for ESRR using a binomial variance showed
the exact opposite relationship. Regardless of the magni-
tude of the RR, the coverage probability of the 95% CI
for ESRR using a binomial variance was greater than
99% when the sample size the overall risk was derived
Table 4 Coverage probability of the 95% confidence interval for the revised product-based estimator (ESRR) using a
binomial variance
Low exposure probability (.05)/Low disease probability in unexposed (.02)
RR/ESR
Sample Size
(N1/N2)
1.0/.02 1.5/.03 2.0/.04 2.5/.05 3.0/.06 4.0/.08 5.0/.10
1,000/1,000 66.1 78.1 83.2 87.1 89.6 88.9 90.0
1,000/5,000 98.9 99.3 99.6 99.7 99.9 99.5 99.5
5,000/1,000 54.4 60.6 61.2 62.3 63.5 64.9 65.0
5,000/5,000 90.0 92.8 92.8 93.7 92.4 94.4 94.8
Low exposure probability (.05)/Moderate disease probability in unexposed (.09)
RR/ESR
Sample Size
(N1/N2)
1.0/.09 1.5/.14 2.0/.18 2.5/.23 3.0/.27 4.0/.36 5.0/.45
1,000/1,000 90.4 91.6 93.2 92.4 92.2 92.0 91.5
1,000/5,000 99.9 100 100 100 99.9 99.7 99.3
5,000/1,000 62.8 63.8 63.9 63.7 62.1 61.6 62.7
5,000/5,000 93.8 93.4 94.2 93.5 93.7 93.6 91.6
High exposure probability (.20)/Low disease probability in unexposed (.02)
RR/ESR
Sample Size
(N1/N2)
1.0/.02 1.5/.03 2.0/.04 2.5/.05 3.0/.06 4.0/.08 5.0/.10
1,000/1,000 89.1 91.2 91.8 92.6 91.5 92.5 93.8
1,000/5,000 99.7 99.1 99.4 99.0 98.0 98.8 98.1
5,000/1,000 63.9 68.0 64.7 69.3 70.7 70.5 71.9
5,000/5,000 92.1 94.0 95.1 94.8 94.3 94.5 93.5
High exposure probability (.20)/Moderate disease probability in unexposed (.09)
RR/ESR
Sample Size
(N1/N2)
1.0/.09 1.5/.14 2.0/.18 2.5/.23 3.0/.27 4.0/.36 5.0/.45
1,000/1,000 92.5 93.2 95.1 94.5 92.6 90.7 86.7
1,000/5,000 99.9 99.7 98.9 98.8 98.2 97.3 95.5
5,000/1,000 66.0 68.3 69.7 69.0 64.4 66.6 66.0
5,000/5,000 94.0 94.0 93.2 94.0 91.9 92.0 88.9
N1 is the sample the overall risk is derived from.
N2 is the sample the relative risk is derived from.
Relative Risk/Exposure-Specific Risk (RR/ESR) values are the hypothesized values.
Italics denote coverage probabilities that did not attain 95%.
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from was 1,000 and the sample size the RR was derived
from was 5,000 (Table 4).
The expected lengths given coverage for Scenario 3 is
shown in Figure 3. Compared to Scenario 1 (Figure 1)
and Scenario 2 (Figure 2), the expected lengths have
decreased substantially. Also, as in Scenario 2, the
expected lengths for all of the 95% CIs increased as the
magnitude of the RR increased.
Scenario 4: High exposure probability (.20)/Moderate
disease probability among unexposed (.09)
In Scenario 4 we increased both the exposure probabil-
ity (.20) and the disease probability among the unex-
posed (.09) at the same time. This gave similar results
to Scenario 3. The observed relative bias of ESRS
increased with increasing RR, while the observed relative
bias was near 0% for ESRR. Coverage probabilities for
the 95% CI of ESRS decreased substantially as the RR
increased. Coverage probabilities for the 95% CIs for
ESRR using a log-based variance and binomial variance
were not affected by the magnitude of the RR. Expected
lengths given coverage also showed similar relationships
that were previously described (Figure 4).
In Scenario 4, we also evaluated the properties of our
estimator when the sample size was 250 for both samples.
We observed similar relationships in terms of observed
relative bias and coverage probabilities. The observed rela-
tive bias of ESRS was 7.8% when the RR was 1.0 and 84.9%
when the RR was 5.0, while the observed relative bias of
ESRR ranged between -1.1% and 1.1%. The coverage prob-
ability of the 95% CI for ESRS was 96.8% when the RR was
1.0 but fell below 95% when the RR was 1.5 (92.3%) and
decreased substantially for a RR of 5.0 (56.8%). The cover-
age probability of the 95% CI for ESRR using a log-based
variance was greater than 95% for all RRs. The coverage
probability of the 95% CI for ESRR using a binomial
Figure 1 Expected length given coverage for 95% confidence intervals of the ESRS, ESRR using a log-based variance, and ESRR using a
binomial variance in Scenario 1. Empirical 95% confidence intervals are also shown. The analysis assumed an exposure probability of .05 and
risk of disease in the unexposed of .02. The x-axis is the magnitude of the RR. Results are from simulations where both N1 and N2 are 5,000.
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variance ranged between 85.7 and 92.5%. In terms of
expected length given coverage, the 95% CI for ESRR using
a binomial variance provided shorter intervals and were
closer to the length of the empirical interval than the 95%
CI using a log-based variance.
Results of the case study
Results of the case study are shown in Table 5. The esti-
mated risk of symptomatic knee OA was slightly higher
when using the simple product-based method. The esti-
mate of the risk of symptomatic knee OA in obese per-
sons ranged between 0.57% and 2.11% when using the
revised product-based method. All 95% confidence inter-
vals overlapped with one another for each age group.
Discussion
We have shown via a simulation study that the simple
product-based estimator (ESRS) that has been calculated
in previous studies only performs well in certain situa-
tions. Mainly, those situations are when the exposure
probability is low (~5%) and the magnitude of the RR is
small (~3.0). There are two reasons for this and they
can easily be seen by deconstructing the overall risk of
disease using the law of total probability.
P(D) P(D|E)*P(E) P(D|E)*P(E)= + (13)
Recall that for the product-based estimator of the ESR
to be unbiased that what we really need is an estimate
of the risk of disease in the unexposed and not the over-
all risk. When the exposure probability is low, less
weight is put on the probability of disease among the
exposed. Put this together with a small RR and most of
the overall risk of disease is being influenced by those
who are unexposed. However, increasing the exposure
probability puts more weight on the risk of disease
Figure 2 Expected length given coverage for 95% confidence intervals of the ESRS, ESRR using a log-based variance, and ESRR using a
binomial variance in Scenario 2. Empirical 95% confidence intervals are also shown. The analysis assumed an exposure probability of .05 and
risk of disease in the unexposed of .09. The x-axis is the magnitude of the RR. Results are from simulations where both N1 and N2 are 5,000.
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among the exposed, which will give you a much more
biased estimate of the risk of disease among the unex-
posed. We also showed that ESRR provides a substantial
improvement over the ESRS in terms of observed rela-
tive bias. We found that the observed relative bias of
ESRR was near 0% in almost all cases.
Coverage probabilities for the 95% CI for ESRS were
inversely related to the observed relative bias of ESRS. As
the observed relative bias increased, the coverage probabil-
ity decreased. The overestimation of the ESR using exist-
ing methodology (ESRS) led to 95% CIs that were less
likely to cover the true ESR. Also, the expected lengths
given coverage for these 95% CIs were usually longer than
the lengths produced for ESRR using either the log-based
variance or the binomial variance rendering this method
of point and interval estimation to be sub-optimal.
Coverage probabilities for the 95% CI for ESRR using a
log-based variance exhibited greater than 95% coverage
in most cases. The exception was when the sample size
for the overall risk was 1,000 and the sample size for
the RR was 5,000. Paradoxically, this was the only situa-
tion in which the 95% CI of ESRR using a binomial var-
iance exhibited greater than 95% coverage. In terms of
expected length given coverage, neither of these two
methods of interval estimation of ESRR performed better
than the other in all situations. The coverage probability
and expected length given coverage depended on the
variance estimate that was employed. From equation 11,
we can see that the log-based variance of ESRR took
into account variability from the overall risk and the RR.
We also assumed that the two measures were indepen-
dent and had a covariance of zero, which is a reasonable
assumption because the two measures come from two
independent samples. From equation 12, we can see
that the binomial variance of ESRR probability of expo-
sure from sample 2 so that the variance would not be
Figure 3 Expected length given coverage for 95% confidence intervals of the ESRS, ESRR using a log-based variance, and ESRR using a
binomial variance in Scenario 3. Empirical 95% confidence intervals are also shown. The analysis assumed an exposure probability of .20 and
risk of disease in the unexposed of .02. The x-axis is the magnitude of the RR. Results are from simulations where both N1 and N2 are 5,000.
Reichmann et al. BMC Medical Research Methodology 2011, 11:1
http://www.biomedcentral.com/1471-2288/11/1
Page 10 of 13
under-estimated. However, in most cases the variability
still was under-estimated. When the sample sizes were
equal, the under-estimation was very little since the cov-
erage probabilities ranged from 87%-95% in most cases.
However in Scenario 1, when the sample size combina-
tion was 1,000/1,000 and the RR was 1.0, 1.5, and 2.0
the coverage probabilities were 66%, 78%, and 83%
respectively.
Figure 4 Expected length given coverage for 95% confidence intervals of the ESRS, ESRR using a log-based variance, and ESRR using a
binomial variance in Scenario 4. Empirical 95% confidence intervals are also shown. The analysis assumed an exposure probability of .20 and
risk of disease in the unexposed of .09. The x-axis is the magnitude of the RR. Results are from simulations where both N1 and N2 are 5,000.
Note: The expected length given coverage for the 95% CI around ESRS could not be computed when the RR was 5.0 because the coverage
probability was 0.
Table 5 Results from the case study on the risk of symptomatic knee OA in obese persons
Age
Overall risk of
symptomatic knee
OA in the Oliveria
study
Risk of symptomatic knee OA
for obese persons using the
simple product-based method
95% CI for
ESRS using a
log-based
variance
Risk of symptomatic knee OA
for obese persons using the
revised product-based
method
95% CI for
ESRR using a
log-based
variance
95% CI for
ESRR using a
binomial
variance
50-
59
0.0040 0.0076 0.0052-0.0110 0.0057 0.0038-0.0085 0.0037-0.0077
60-
69
0.0087 0.0167 0.0121-0.0230 0.0125 0.0089-0.0175 0.0095-0.0155
70-
79
0.0147 0.0282 0.0207-0.0383 0.0211 0.0153-0.0289 0.0168-0.0253
*Probability of being obese was derived from the Niu study (0.371).
**RR of symptomatic knee OA for obese persons was derived from the Niu study (1.91).
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The four scenarios, which were defined by the combi-
nations of two different exposure probabilities (.05 and
.20) and two different probabilities of disease in the
unexposed (.02 and .09), did not affect the observed
relative bias of ESRR. However, as we increased these
two parameters, the observed relative bias of ESRS
increased. This phenomenon was also demonstrated
when comparing coverage probabilities based on the
log-based variance for ESRR and ESRS. When comparing
coverage probabilities based on the binomial variance
for ESRR, the scenario does matter with larger values of
the probability of exposure and/or probability of disease
in the unexposed increased coverage probabilities. This
is not surprising because the estimate of the binomial
variance will increase with increasing exposure probabil-
ities and increasing probability of disease among the
unexposed.
Results from our case study most closely resemble
scenario two where the magnitude of the RR is 2.0. In
scenario two, we assumed an exposure probability of
0.20 and a probability of disease in the unexposed of
.02. In our case study the RR was 1.91, the exposure
probability (probability of being obese) was 0.371, and
the overall risk of disease (symptomatic knee OA) ran-
ged from 0.0087 to 0.0132. While the simulations sug-
gest that the estimator would be biased, the overall
risk of disease is small so the difference between the
two estimates in absolute terms is not large with the
largest over-estimation occurring in those ages 70-79
by 0.71%.
It is likely that the estimates produced by Horsburgh
and Stewart et al. were accurate. In the article by Hors-
burgh et al on tuberculosis, he estimated the ESR of
tuberculosis for those with advanced HIV infection; old,
healed tuberculosis; and immunosuppressive therapy[1].
While the RR of obtaining a new case of tuberculosis is
high for those with advanced HIV infection and old,
healed tuberculosis, the probability of exposure is so low
for these exposures that the impact of the large RR
would be muted. For those with immunosuppressive
therapy, the RR of a new case of tuberculosis is modest
(2.0) and the probability of exposure is low so the over-
all probability of disease is a good estimate of the prob-
ability of disease among those who are not on
immunosuppressive therapy [1]. In the Stewart article,
the largest RR is 4.62, but this corresponds to an expo-
sure probability of 0.001. When the exposure probabil-
ities are large enough to possibly impact the estimate of
the ESR, the RR is low enough (< 2.0) to offset the pos-
sible bias [2].
An article by Cupples et al. calculated risk curves for
first-degree relatives of patients with Alzheimer’s dis-
ease. Their method used the odds ratio instead of the
relative risk and included converting probabilities to
odds [6]. Our method will allow clinicians and other
researchers to find the ESR in one step, provided the
summary statistics needed for the calculation (P1(D),
RR2, and P2(E)) are available.
We acknowledge that there are limitations with this
study. The first is that simulation studies can not be
considered a proof. However, we did show mathemati-
cally that the proposed estimator of the ESR is unbiased
and the results of our simulation confirm this finding. It
would be important to show mathematically what the
true coverage probabilities are for our 95% CIs across
different RRs, exposure probabilities, and probabilities of
disease among the unexposed. We also acknowledge
that our simulations showed coverage probabilities that
well exceed 95% when we are calculating 95% CIs for
ESRR using a log-based variance.
We also evaluated the properties of our point and
interval estimators when the sample size was small. We
observed that one should only consider carrying out
these calculations in smaller samples if the prevalence of
exposure and disease among the unexposed is suffi-
ciently large. If one of these values is small than the
validity of the estimate of the RR may be questionable.
Thus, we recommend that investigators using this meth-
odology only use estimates that are of the highest
quality.
The implications of our study are substantial. Clini-
cians can use these estimates to better explain risk of
disease to patients. Many times clinicians and patients
can misinterpret the meaning of having a certain RR of
disease. Interpreting the probability of disease given a
certain exposure (the ESR) is much more transparent.
Future studies that examine the calculation of ESRs may
look at the impact of having the odds ratio (OR) rather
than the RR. Also, the consideration of under which
study designs and magnitudes of the exposure/disease
would an approximation using the OR be valid is an
important question to answer. It is likely that the OR
would be valid when the prevalence of the outcome is
less than 10% but examining this rigorously would be of
great importance [7]. Lastly, re-sampling and bootstrap-
ping techniques may be a useful method of obtaining
CIs with appropriate coverage.
Conclusions
We developed a new estimator for the ESR from two
independent samples that exhibits more desirable prop-
erties with respect to bias and coverage than the existing
methodology. The existing methodology will still per-
form well when the exposure probability is low. Future
methodological studies should focus on the impact of
ORs and re-sampling techniques.
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